 | | Vol. 10.20 – 28 October, 2024 |
| |
|
|
| Investigators assembled a comprehensive multi-omics reference atlas of prenatal human skin, combining single-cell and spatial transcriptomics data, to characterize the microanatomical tissue niches of the skin.
[Nature] |
|
|
|
 | | PUBLICATIONSListed by the impact factor of the journal |
| | DERMAL STEM CELLS & TISSUE REGENERATION |
|
|
|
| Scientists analyzed formalin-fixed, paraffin-embedded, archived skin tissue biopsies of three types of cutaneous drug reactions with varying severity and quantified more than 5,000 proteins in keratinocytes and skin-infiltrating immune cells.
[Nature] |
|
|
|
| Using assay of transposase-accessible chromatin sequencing, researchers discovered altered chromatin landscapes in irradiated fibroblasts, with thrombospondin 1 identified as a crucial epigenetically primed wound repair-related gene.
[Nature Communications] |
|
|
|
| Investigators presented clinical evidence for the regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in two randomized, double-blind, placebo-controlled Phase Ib trials in patients with moderate-to-severe atopic dermatitis or chronic plaque psoriasis.
[Nature Communications] |
|
|
|
| Scientists investigated the monocyte chemotactic protein 1-induced protein 1 (MCPIP1) RNase-dependent miRNA‒mRNA regulatory network in chemically induced squamous cell carcinoma-like skin papillomas.
[Journal of Experimental & Clinical Cancer Research] |
|
|
|
| Researchers identified circASH1L(4,5) and its interaction with miR-129-5p, both of which increased during human skin wound healing. circASH1L enhanced miR-129 stability and silencing activity by protecting it from target-directed degradation triggered by NR6A1 mRNA.
[British Journal of Dermatology] |
|
|
|
| The authors showed multiple senescence-related changes in melanocytes and in fibroblasts of CDKN2A-deficient patients
[Aging Cell] |
| |
|
|
| FTSJ1-deficient cells were more sensitive to oxidative stress and showed decreased metastatic colonization in xenograft models of melanoma metastasis.
[Nature Cancer] |
|
|
|
| The authors identifed IFI16 as a key sensor during IFN-γ stimulation associated with immune checkpoint inhibitor (ICI) response, and proposed the epigenetic EZH2 inhibitor as an alternative treatment strategy to overcome ICI resistance in patients with metastatic melanoma.
[Journal of Clinical Investigation] |
|
|
|
| Researchers identified Apolipoprotein E as the top lipid-metabolism gene segregating the melanoma MITFhigh/AXLlow proliferative/ferroptosis-resistant from MITFlow/AXLhigh invasive/ferroptosis-sensitive state.
[Science Advances] |
|
|
|
| This study evaluated neoadjuvant tavokinogene telseplasmid delivered by electroporation combined with intravenous nivolumab followed by surgery and adjuvant nivolumab in patients with operable locoregionally advanced melanoma.
[Clinical Cancer Research] |
|
|
|
| Investigators demonstrated that eIF4F was essential for controlling extracellular signal-regulated kinase signaling intensity in treatment-naïve melanoma cells harboring BRAF or NRAS mutations.
[Proceedings of The National Academy of Sciences of The United States of America] |
|
|
|
|
| The authors discuss the process of neutrophil extracellular transformation (NETs), explore the interactions between NETs and skin cells, and examine therapeutic strategies targeting NETs and drug delivery platforms to accelerate wound healing.
[Trends in Pharmacological Sciences] |
|
|
|
|
| The Albanese Government is investing $10.3 million to tackle the most common cancer in Australia, skin cancer. This funding will bring together the expertise of the cancer sector and accelerate the development of a national targeted skin cancer screening roadmap.
[Department of Health and Aged Care] |
|
|
|
| Arcutis Biotherapeutics, Inc. announced that its wholly-owned subsidiary Arcutis Canada, Inc. has received regulatory approval from Health Canada for ZORYVE topical foam 0.3% for the treatment of seborrheic dermatitis in patients nine years of age and older.
[Arcutis Biotherapeutics, Inc.] |
|
|
|
|
| December 8-11, 2024
Whistler, British Columbia, Canada |
|
|
|
|
|
| | The Wistar Institute – Philadelphia, Pennsylvania, United States |
|
|
|
| | University of Pittsburgh – Pittsburgh, Pennsylvania, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | University of Wisconsin Madison – Madison, Wisconsin, United States |
|
|
|
| | The Chinese Institutes for Medical Research (CIMR) – Beijing, China |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
